Veterinary Vaccine Nanoadjuvants for C. difficile Infection Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current veterinary vaccines for Clostridium difficile infections in birds and mammals are inefficient and can induce immune responses or allergies due to the presence of proteins in adjuvants, and existing therapies based on whole bacterial cells have low therapeutic antibody fractions.
Innovation Solution
A veterinary vaccine comprising nanoadjuvants in the form of an oil-in-water emulsion with epitopes of Clostridium difficile surface proteins (71 kDa and M24) conjugated with carrier proteins, along with Clostridium difficile toxins TcdA and TcdB, and immunomodulating compounds like monophosphorylated lipid A, polysaccharides, and teichoic acids, using synthetic oil and specific detergents to enhance immune response without inducing allergies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If whole bacterial cells are used as vaccine components, then the immune response is stimulated, but the therapeutic antibody fraction is low and the vaccine efficiency is poor
Solution Approach 1:
The patent extracts and isolates specific immunogenic components (toxins TcdA and TcdB, surface proteins 71 kDa and M24, teichoic acids) from whole C. difficile bacterial cells. This extraction process concentrates the therapeutic antibody-inducing components while removing non-essential bacterial material, thereby increasing the therapeutic antibody fraction and vaccine efficiency.
Solution Approach 2:
The vaccine divides the complex whole bacterial cell into distinct functional segments: toxins (TcdA, TcdB), surface proteins (71 kDa, M24), and immunomodulating compounds (teichoic acids). Each segment is purified and combined in optimized proportions to maximize therapeutic antibody production while improving overall vaccine reliability.
2Reliability
If protein-containing adjuvants are used to enhance immune response, then the immune response is stimulated, but immune responses or allergies are induced
Solution Approach 1:
The patent fundamentally changes the chemical composition parameters of the adjuvant system by replacing protein-based adjuvants with a synthetic nanoadjuvant composed of mineral oil, cationic detergent (CPC), non-ionic detergent (Tween 80), and organic solvent (ethanol). This parameter change eliminates protein allergens while maintaining adjuvant functionality, thus stimulating immune response without inducing allergies.
Solution Approach 2:
The patent creates a composite nanoadjuvant material combining mineral oil (carrier), cationic detergent (surface active agent), non-ionic detergent (emulsifier), and organic solvent (co-solvent). This composite material achieves effective immune stimulation through synergistic interactions of its components while avoiding the harmful allergic effects associated with protein-containing adjuvants.
3Device complexity
If vegetable oil is used in nanoemulsion, then the nanoemulsion is formed, but protein traces induce immune response or allergy
Solution Approach 1:
The patent removes protein-containing vegetable oils from the nanoemulsion formulation and replaces them with protein-free mineral oil. This extraction of harmful protein traces from the oil phase eliminates the source of unwanted immune responses and allergies while preserving the nanoemulsion's ability to enhance vaccine immunogenicity.
Solution Approach 2:
The patent changes the oil phase composition parameter from vegetable oil (protein-containing) to mineral oil (protein-free). This parameter change maintains the nanoemulsion's physical properties and adjuvant function while eliminating protein traces that would otherwise induce unwanted immune responses or allergies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine induces a significant increase in therapeutic antibody production, is safe for use in birds and mammals, and effectively prevents C. difficile infections by stimulating a targeted immune response without causing adverse reactions.
Implementation Method 1
Nanoemulsion particles charged in such a way can interact with the cell membrane of immunocompetent cells, including antigen-presenting cells. Efficient sampling of the nanoemulsion-bound antigen accelerates the processing of the antigen by APC
Data Source
AI summary
The present invention relates to a veterinary vaccine containing nanoadjuvants in the form of emulsion and Clostridium difficile antigens, as well as the use of the vaccine in the preventions and treatment of a C. difficile infection, especially in birds and mammals. The object of the invention is also the use of this vaccine to produce C. difficile-specific antibodies.